On October 28, 2020, the President of the Republic of Kazakhstan Kassym-Zhomart Tokayev accepted the General Director of the Research Institute for Biological Safety Problems Kunsulu Zakarya.
Kassym-Jomart Tokayev heard information about the main results on the development of a coronavirus infection domestic vaccine.
Kunsulu Zakarya, informed the President that on five platforms on the basis of RIBSP, work to develop COVID-19 vaccines is currently underway. The inactivated vaccine developed by the Institute has been approved by the World Health Organization (WHO) and has passed the first phase of clinical trials. The second phase of clinical trials is currently underway at the National Research Center for Phthisiopulmonology.
Illustrative photo: from open sources
The coronavirus infection subunit domestic second vaccine, which is now on the stage of development, is also approved by the WHO and has successfully passed preclinical studies.
Kunsulu Zakarya reported to the President on the construction of a plant on the territory of the RIBSP for the production of domestic immunobiological preparations with a design capacity of 60 million doses of vaccines per year.
On the meeting, the prospects for the development of RIBSP, increasing the salaries of scientists, attracting young specialists, as well as introducing the concept of “temporary registration of a vaccine” in regulatory legal acts were also discussed. Following the meeting, the President supported the proposal to increase the volume of housing construction for employees of the Institute.
At the end of the meeting, the Head of State gave a number of specific instructions on the development of domestic vaccines. www.akorda.kz